Jan Adolfsson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8613587/publications.pdf

Version: 2024-02-01

932766 839053 21 876 10 18 citations g-index h-index papers 22 22 22 1607 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Prostate cancer screening in men aged 50–69 years (STHLM3): a prospective population-based diagnostic study. Lancet Oncology, The, 2015, 16, 1667-1676.	5.1	308
2	Absolute and Relative Risk of Cardiovascular Disease in Men With Prostate Cancer: Results From the Population-Based PCBaSe Sweden. Journal of Clinical Oncology, 2010, 28, 3448-3456.	0.8	173
3	Risk of thromboembolic diseases in men with prostate cancer: results from the population-based PCBaSe Sweden. Lancet Oncology, The, 2010, 11, 450-458.	5.1	110
4	Prostate Cancer Diagnostics Using a Combination of the Stockholm3 Blood Test and Multiparametric Magnetic Resonance Imaging. European Urology, 2018, 74, 722-728.	0.9	70
5	Mortality Among Men with Locally Advanced Prostate Cancer Managed with Noncurative Intent: A Nationwide Study in PCBaSe Sweden. European Urology, 2011, 60, 554-563.	0.9	65
6	The Stockholm-3 (STHLM3) Model can Improve Prostate Cancer Diagnostics in Men Aged 50–69 yr Compared with Current Prostate Cancer Testing. European Urology Focus, 2018, 4, 707-710.	1.6	42
7	Multiple Events of Fractures and Cardiovascular and Thromboembolic Disease Following Prostate Cancer Diagnosis: Results From the Population-Based PCBaSe Sweden. European Urology, 2012, 61, 690-700.	0.9	15
8	Detection of Prostate Cancer Using a Multistep Approach with Prostate-specific Antigen, the Stockholm 3 Test, and Targeted Biopsies: The STHLM3 MRI Project. European Urology Focus, 2017, 3, 526-528.	1.6	14
9	Predictors of participation in risk-based prostate cancer screening. PLoS ONE, 2018, 13, e0200409.	1.1	12
10	Mortality in men with castrationâ€resistant prostate cancer—A longâ€term followâ€up of a populationâ€based realâ€world cohort. BJUI Compass, 2022, 3, 173-183.	0.7	12
11	Long-term adherence to GnRH agonists in men with prostate cancer. A nation-wide population-based study in prostate cancer data base Sweden. Scandinavian Journal of Urology, 2020, 54, 20-26.	0.6	11
12	Bringing two worlds closer together: a critical analysis of an integrated approach to guideline development and quality assurance schemes. BMC Health Services Research, 2021, 21, 172.	0.9	11
13	The use of palliative medications before death from prostate cancer: Swedish population-based study with a comparative overview of European data. European Journal of Cancer, 2018, 88, 101-108.	1,3	10
14	Guideline-based quality assurance: a conceptual framework for the definition of key elements. BMC Health Services Research, 2021, 21, 173.	0.9	9
15	Integrating Quality Assurance and Quality Improvement With Guidelines: Systematic Stakeholder-Driven Development of an Extension of the Guidelines International Network–McMaster Guideline Development Checklist. Annals of Internal Medicine, 2022, 175, 735-739.	2.0	6
16	Poor Follow-up After Elevated Prostate-specific Antigen Tests: A Population-based Cohort Study. European Urology Focus, 2019, 5, 842-848.	1.6	4
17	The STHLM3-model, Risk-based Prostate Cancer Testing Identifies Men at High Risk Without Inducing Negative Psychosocial Effects. European Urology Open Science, 2021, 24, 43-51.	0.2	2
18	The GIN-McMaster guideline tool extension for the integration of quality improvement and quality assurance in guidelines: a description of the methods for its development. Journal of Clinical Epidemiology, 2023, 154, 197-203.	2.4	2

#	Article	IF	CITATIONS
19	Do false-positive screening results affect screening behavior for prostate cancer?. Nature Reviews Urology, 2005, 2, 272-273.	1.4	O
20	Reply to Tommaso Cai, Carolina D'Elia, and Beatrice Detti's Letter to the Editor re: Mieke Van Hemelrijck, Hans Garmo, Lars Holmberg, et al. Multiple Events of Fractures and Cardiovascular and Thromboembolic Disease Following Prostate Cancer Diagnosis: Results From the Population-Based PCBaSe Sweden. Eur Urol 2012;61:690–700. European Urology, 2012, 61, e28.	0.9	0
21	Citing and endpoints. Scandinavian Journal of Urology, 2022, 56, 213-213.	0.6	0